Pharming Group (NASDAQ:PHAR) Releases Earnings Results, Misses Expectations By $0.02 EPS

Pharming Group (NASDAQ:PHAR) released its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02), Zacks reports. The firm had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Price Performance

Shares of NASDAQ:PHAR opened at $8.77 on Friday. The company’s fifty day moving average price is $8.99 and its 200-day moving average price is $8.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10. Pharming Group has a one year low of $6.65 and a one year high of $11.80.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PHAR shares. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Friday. Jefferies Financial Group began coverage on Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Oppenheimer boosted their target price on Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research report on Friday.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.